The herpes simplex virus thymidine kinase (HSV-TK) gene is being developed in the treatment of many different types of tumors. The HSV-TK gene sensitizes tumor cells to the antiviral drug ganciclovir (GCV) and mediates the bystander effect in which unmodified tumor cells are killed as well. Although this approach has shown a significant antitumor effect, the need to potentiate this therapy exists. The results of this study indicate that recombinant interferon ␣2a (IFN␣2a) acts synergistically with GCV to kill HSV-TK-expressing PA1 human ovarian tumor cells. Furthermore, it enhances the bystander killing of nearby unmodified tumor cells that do not express the HSV-TK gene. Previous studies have suggested that in vitro and in vivo bystander effects may be mediated by different mechanisms. However, IFN␣2a enhanced bystander killing in both systems, with the survival of mice bearing preexisting tumors being significantly prolonged when they were treated with IFN␣2a and HSV-TK/GCV compared with either treatment alone. Mechanism studies have shown that treatment with IFN␣2a and GCV caused an increase in cells in S phase 24 hours after therapy in the HSV-TK-expressing cells, but the mechanism of action of IFN␣2a does not seem to be related to an increase in DNA damage, because GCV incorporation was not increased after treatment with IFN␣2a. These findings suggest that IFN␣2a may be a useful adjunctive therapy for the HSV-TK/GCV system.
T he herpes simplex virus thymidine kinase (HSV-TK) gene therapy system has been used widely for the experimental therapy of a number of different tumors, with over two dozen clinical trials currently underway. Although some success has been achieved in these trials, many patients have not responded, and improvements are necessary for this therapy to be effective.
The HSV-TK system is based on the observation that cells modified with this gene are killed by the antiviral drug ganciclovir (GCV), which is a derivative of acyclovir. 1 This susceptibility to GCV reflects the ability of the viral TK to monophosphorylate the drug ϳ1000 times more efficiently than the mammalian enzyme. Once monophosphorylated, the drug can be di-and triphosphorylated by normal cellular enzymes into a toxic compound that inhibits DNA polymerase and may act as a chain terminator. 2, 3 Because it is not possible to genetically alter all cells in a tumor, therapeutic use of this system depended upon the discovery of a complex mechanism, termed the bystander effect, in which preexisting tumor cells that do not express the HSV-TK gene were killed when exposed to HSV-TK-expressing cells and GCV. 4 -7 Unfortunately, even with bystandermediated toxicity, not all of the tumor cells in a mixed population are killed under some circumstances, as evidenced by residual tumor cells in animal models. 8 Improvements in gene therapy technology (e.g., more efficient gene transfer) and the use of this therapy in combination with other agents will likely enhance its efficacy. In addition, other approaches that enhance the bystander effect need to be explored to enhance the antitumor effect even in situations in which there is efficient gene transfer. Recent studies have begun to elucidate the in vivo mechanism of the bystander effect. A cytokine cascade is generated when the HSV-TK gene-modified tumor cells die after being exposed to GCV. These cytokines have been shown to be involved in mediating the in vivo bystander effect. Proinflammatory cytokines such as tumor necrosis factor, interleukin-1 (IL-1), and IL-6 are predominantly observed. 9 For these reasons, we have been investigating recombinant interferon ␣2a (IFN␣2a) in combination with the HSV-TK/GCV system. IFN␣2a and a GCV analog, acyclovir, have been used together to treat herpes virus infections, with apparent synergy in other systems. 10, 11 In addition, previous studies showed that IFN␣2a had a synergistic effect on the growth inhibition of tumor cells with a different nucleoside analog that also damages DNA, 3Ј-azido-3Ј-deoxythymidine or zidovudine. 12 We sought to determine whether IFN␣2a would also result in synergistic growth inhibition in combination with GCV in the HSV-TK system and to investigate the underlying mechanisms. The results show that at minimally toxic doses of IFN␣2a, a significant synergistic increase in tumor cell killing was achieved. Furthermore, growth inhibition was seen in mixed populations of HSV-TKpositive and -negative cells, demonstrating an enhanced bystander effect. Animal treated with IFN␣2a and HSV-TK/GCV showed significant increased survival compared with animals receiving either treatment alone, confirming an enhanced in vivo bystander effect. This result may have implications for the therapeutic use of IFN␣2a in combination with HSV-TK.
These results suggest that the combination of HSV-TK/GCV and IFN␣2a may be more effective as a treatment for cancer than HSV-TK/GCV alone.
MATERIALS AND METHODS

Cell lines
The PA1 human ovarian tumor and KBALB murine fibrosarcoma cell lines were obtained from the American Type Culture Collection (Manassas, Va) and transduced with retroviral vectors as described previously. 4 The 
Cell culture
All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine sera (Life Technologies, Grand Island, NY), 2 mM glutamine (Life Technologies), and 1 mM nonessential amino acids (Life Technologies) at 37°C in a 5% CO 2 incubator. Cells were passaged at ϳ75% confluence.
Cytotoxicity assays
Both colony-forming and neutral red assays were used to evaluate cytotoxicity.
For colony-forming assays, 500 PA1 or PA1STK or mixtures of 50% of each type of cell were plated per well in a six-well dish (Corning, Corning, NY) and incubated for 24 hours. GCV (Syntex, Palo Alto, Calif) and/or recombinant IFN␣2a␣2a (Hoffman-La Roche, Nutley, NJ) were added at varying doses and incubated for 7 days. Colonies were stained with 0.5% crystal violet (Sigma, St. Louis, Mo) and enumerated. Control colonies contained ϳ60 cells; a colony was defined as a group of Ն40 cells. Experiments were repeated a minimum of three times.
For the neutral red assay, 10,000 PA1 or PA1STK or mixtures of 50% of each type of cell were plated in 96-well dishes and allowed to adhere. Varying doses of GCV and IFN␣2a were added, and the cells were stained with the supravital stain neutral red after 4 days (Sigma). This assay measures the number of live adherent cells, has been described previously, 13 and was validated for the PA1 and PA1STK cells. Experiments were repeated a minimum of three times.
The SD is reported for all error bars.
In vivo analysis
Female BALB/c mice were obtained at 5-6 weeks of age from Charles River Laboratories (Wilmington, Mass) and were maintained according to established guidelines. Tumors were established by injecting KBALB-LNL tumor cells (2 ϫ 10 5 cells in Dulbecco's modified Eagle's medium) intraperitoneally (i.p.) using a 26-gauge needle. Tumors were allowed to grow for 3 days before treatment with IFN␣2a/GCV/HSV-TKexpressing cells was begun. Animals were treated with either IFN␣2a (2.5 ϫ 10 6 international units (IU) mg/kg) alone, PA1STK cells (2 ϫ 10 7 lethally irradiated cells) plus GCV (150 mg/kg), or a combination of the two. Control groups received KBALB-LNL alone. All agents were injected i.p. concomitantly. Treatment of all groups was administered once a day for 5 days. The survival of animals is reported as the outcome measure; animals with tumors were sacrificed according to University Animal Care Guidelines when the tumor exceeded 1 g, their movement was impeded, or they lost the righting reflex.
GCV incorporation
PA1STK cells were plated at 10 6 cells in a 75-cm 2 flask (Corning) and allowed to adhere overnight. Next, cells were incubated with varying dilutions of [ 3 H]GCV (14.6 Ci/mmol) for 24 hours, harvested, and counted. Cells were centrifuged, and 1 mL of 0.2N perchloric acid was added. Cells were washed three times in 1 mL of 0.2N perchloric acid, and the pellet was resuspended in 350 L of 0.1 M sodium acetate and 5 mM magnesium sulfate. The suspension was added to a scintillation vial containing 15 mL of Ecolite scintillation cocktail (ICN Biochemicals, Costa Mesa, Calif), and radioactivity was quantified on a Beckman LS 6500 scintillation counter (Fullerton, Calif). Data from three experiments are shown. 
Cell cycle analysis
RESULTS
To determine the effects of combination therapy (HSV-TK/GCV and IFN␣2a) on each population of HSV-TKpositive and -negative cells, these cells were exposed to the agents either separately or together. Data for this set of experiments were derived from the colony-forming assay and confirmed with the neutral red assay. The plot shown is derived from all data obtained. Figure 1a shows an isobologram analysis of the gene-modified PA1STK cells in which the effects (as determined by the 50% inhibitory concentration (IC 50 )) of the addition of IFN␣2a on the concentration of GCV necessary to achieve 50% inhibition of cell growth or cytotoxicity were determined. The isobologram analysis plots the IC 50 values of the two agents separately on the axes, and the points are shown for the combinations of the two agents at varying concentrations. The IC 50 of GCV alone was ϳ0.03 M, and the IC 50 of IFN␣2a alone was ϳ250,000 IU/mL. When a dose of IFN␣2a as low as 100 IU/mL was added, the IC 50 of GCV dropped to ϳ0.006 M (6 nM). Doses of IFN␣2a of Յ3000 IU/mL slightly enhanced this effect further, with no increase in cytotoxicity attributed to the IFN␣2a alone. The effect of IFN␣2a appears to plateau at ϳ3000 IU/mL, as doses of 50,000 IU did not further decrease the IC 50 of GCV. These experiments were conducted in duplicate and repeated three times. This figure demonstrates synergism between the two agents.
The results of parallel studies carried out in unmodified parent PA1 cells that do not express HSV-TK are summarized in Figure 1b . Synergistic effects on cytotoxicity and growth inhibition were observed in these cells also. The effect was not as dramatic in these cells, however, because the addition of IFN␣2a lowered the IC 50 of GCV by a factor of two as opposed to a factor of six for the gene-modified cells. Thus, it appears that the change in cytotoxicity in PA1STK cells was not entirely the result of an IFN␣2a-induced increase in mammalian TK activity, because a much greater increase in cytotoxicity occurred in HSV-TK-expressing PA1 cells than in controls.
GCV is toxic to cells by disrupting DNA synthesis and repair, which occur during the S phase of the cell cycle. To determine whether IFN␣2a affected progression through the cell cycle, we analyzed the cell-cycle profiles of treated and control cells. When cells were treated with IFN␣2a or a low dose of GCV (0.005 M), only minimal changes were observed on the cell cycle. As shown in Figure 2 One hypothesis for the increase in cell death of the HSV-TK gene-modified cells with both increasing doses of GCV and IFN␣2a is that the increase in cells in S phase allows a greater amount of GCV to be incorporated into DNA. To determine whether IFN␣2a enhanced the toxicity of GCV by allowing a greater amount of GCV to be incorporated, PA1STK cells were incubated with varying doses of [ 3 H]GCV in the presence or absence of IFN␣2a. As shown in Figure 3 , the incorporation of GCV into cellular DNA increased in a linear manner with increasing concentrations of GCV added to the culture; however, the addition of IFN␣2a had no significant effect on incorporation at concentra- Concentrations of IFN␣2a of Ͼ50,000 IU/mL were not evaluated, because no further enhancement was observed from 3000 IU/mL to 50,000 IU/mL. Error bars are SDs for both figures. b: Isobologram analysis of combination therapy of GCV and IFN␣2a on parent (unmodified) PA1 cells. The same analysis described in (a) is shown for unmodified cells in (b). The parent cells had a similar IC 50 value for IFN␣2a (250,000 IU/mL) and a much greater value for GCV (100 M), which would be expected. As with the gene-modified cells, IFN␣2a lowered the IC 50 value of GCV, but only by a factor of 2, and this effect also reached a plateau at ϳ3000 IU/mL IFN␣2a. tions of 0.005 M of GCV (Fig 3) or 0.05 M of GCV (data not shown). Thus, the effects of IFN␣2a on the cell cycle may be unrelated to the synergism, and the IFN␣2a-enhanced cytotoxicity was not likely to be a result of increased GCV-induced DNA damage, although qualitative rather than quantitative factors may play a role.
Therapeutic use of the HSV-TK system depends upon bystander killing of unmodified tumor cells. Therefore, for an adjunctive therapy to be effective, it must increase cells. An increase in incorporation was observed with increasing concentrations of GCV, but the addition of IFN␣2a had no effect on the incorporation.
the ability of the HSV-TK-expressing cells to kill unmodified HSV-TK-negative tumor cells. We analyzed the influence of IFN␣2a on the bystander effect. Figure  4 shows that IFN␣2a synergistically enhances the killing of an entire population of cells when only 50% of a mixed population of tumor cells contains the HSV-TK gene. Furthermore, a population containing 100% HSV-TK cells exhibits a similar response to combination therapy with IFN␣2a and GCV as a mixed population. The increased cytotoxicity of GCV in a mixed population is shown through the lowering of the IC 50 of GCV from 0.03 M without IFN␣2a to ϳ0.005 M with IFN␣2a. Thus, the addition of IFN␣2a seems to enhance the HSV-TK/GCV-generated bystander effect in vitro.
To determine whether IFN␣2a would enhance the HSV-TK/GCV-mediated killing of a preexisting tumor, mice were inoculated i.p. with a murine fibrosarcoma tumor (KBALB). Tumor cells were injected into mice, allowed to grow to establish a preexisting tumor before the institution of therapy, and subsequently treated with HSV-TK gene-modified cells/GCV alone, IFN␣2a alone, or a combination of the two. As shown in Figure  5 , IFN␣2a alone had only a minimal effect on survival. Survival was significantly prolonged (P ϭ .0176) when IFN␣2a was used in conjunction with HSV-TK/GCV therapy compared with HSV-TK/GCV therapy alone.
DISCUSSION
The ability to augment the antitumor effect of HSV-TK is critical to the development this gene therapy approach for the treatment of cancer. The use of the HSV-TK gene has shown that an antitumor effect can be generated that will prolong animal survival in tumor-bearing mice. Furthermore, early clinical trials have also shown that this approach can be used safely as a tumor therapy. However, in both animal models and human trials, long-term cure has been difficult to achieve. Several methods have been used in combination to enhance the antitumor efficacy of HSV-TK/GCV therapy, which is dependent upon the generation and augmentation of the bystander effect, which may involve both the observed in vitro mechanism of transfer of toxic metabolites and also an in vivo generation of an immune/inflammatory response. In one example, immunization to tumor cells before treatment with the HSV-TK gene-modified cells and GCV resulted in prolonged animal survival. 14 Our results confirm and extend previous findings using IFN 15, 16 by demonstrating the importance of this combination in a therapeutic tumor model and analyzing the underlying mechanism that leads to a synergistic antitumor effect. We have demonstrated that a low dose of IFN␣2a decreased the IC 50 of GCV from 0.03 M to 0.005 M in PA1STK cells. Studies have shown that some residual tumor cells in animals treated with GCV still express the HSV-TK gene, suggesting that delivery of GCV to the site of the tumor may be a limiting factor in the efficacy of this therapy. 8 Thus, an enhanced susceptibility to GCV by IFN␣2a may allow a lower delivered dose of GCV to be more toxic. In unmodified tumor cells, the IC 50 of GCV was lowered from 100 M to 50 M, which was still synergistic but less dramatic, suggesting that the mechanism of action was not the result of an IFN␣2a-induced increase in mammalian TK activity. These results are consistent with a previous study in herpes-infected cells in which a synergistic cytotoxic effect was observed with the combination of acyclovir and IFN␣2a␣2a. 10 The mechanism of action in that system was not clear, but did not seem to involve changes in TK activity.
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A critical feature of the therapeutic use of the HSV-TK/GCV system involves bystander killing of unmodified, preexisting tumor cells. The results of this study indicate that IFN␣2a and GCV act synergistically to kill tumor cells in the HSV-TK system, both in vivo and in vitro. Survival of mice with a preexisting tumor was significantly prolonged when IFN␣2a was included in the HSV-TK/GCV therapy compared with the HSV-TK/ GCV alone. The in vitro and in vivo bystander effects may be mediated through different mechanisms. In vitro bystander killing is thought to be mediated by the transfer of toxic metabolites 6, 17 through gap junctions, 18 and connexins are required for this process in some systems. 19 The in vivo effect is thought to be related to the generation of a local immune response against the tumor, and specific cytokines have been shown to be liberated at the site of the tumor, 9 although the transfer of toxic metabolites may also play a role. IFN␣2a may also contribute to both of these mechanisms, because it seems to enhance both the in vivo and the in vitro bystander effects as well as the cytotoxic effects of GCV on populations of HSV-TK gene-modified tumor cells in which all of the cells express the HSV-TK gene.
IFN␣2a has been shown in many models to have antitumor and immune-stimulatory effects, and some experimental gene therapies have been tested involving modification of cells with IFN␣2a alone. Thus, IFN␣2a may be acting both as an immune regulatory agent to enhance the immune-mediated killing of the unmodified tumor and may also allow the HSV-TK-expressing cells to be toxic to the nearby unmodified tumor. The in vivo bystander effect is mediated through an immune/inflammatory process that involves an early component and a separate later one. In the first several days after GCV therapy, proinflammatory cytokines are released within the tumor and are an integral part of the bystander effect. Weeks after therapy, the dying GCV-exposed HSV-TK tumor cells lead to a delayed hypersensitivity immune response, because GCV is not immunosuppressive. 9, 14 Thus, studies with IL-2 in combination with GCV therapy did not enhance the early phase bystander killing but did enhance the later long-term tumor immunity. Therefore, it would be expected that cytokines that enhance the early phase of the bystander effect (proinflammatory) would enhance the antitumor response. Our results with IFN␣2a agree with the currently recognized model of enhancement of the bystander effect.
Cell cycle analysis shows that at 24 hours posttreatment, a significantly larger number of cells is in S phase for the cells that were treated with the combination therapy compared with those treated with HSV-TK/ GCV alone. Previous studies have shown that GCV uptake was related to growth inhibition of HSV-TKexpressing cells, 20 which led us to hypothesize that IFN␣2a might be increasing the percentage of cells in S phase, allowing them to increase their incorporation of GCV into DNA. However, because IFN␣2a did not enhance the incorporation of GCV into DNA, it is not likely that the increased number of cells in S phase induced by the addition of IFN␣2a reflects an increase in DNA damage, although more qualitative effects rather than quantitative effects may be responsible. It is possible that cells are being retained in S phase to repair the DNA damage caused by GCV incorporation, but that IFN␣2a inhibits the ability of these cells to repair damage, as was observed in other systems. 12 Further studies will be necessary to evaluate this hypothesis.
In summary, IFN␣2a enhances the GCV mediated killing of HSV-TK expressing cells and nearby unmodified cells in a synergistic manner both in vivo and in vitro. Although the mechanism of action is not clearly defined, it does not seem to be a result of increased GCV incorporation into DNA and may be related to the ability of IFN␣2a to disrupt DNA damage assessment and/or repair. These findings suggest that IFN␣2a may be a useful adjunctive therapy for the HSV-TK/GCV system because its mechanism of action enhances both the chemotoxic activity of GCV and the immunostimulatory action of the dying GCV exposed HSV-TK genemodified tumor cells.
